Emerging research has shed light on the possibility of generic drugs being repurposed for the treatment of COVID-19. Dr. John Buse discusses metformin, ivermectin, and fluvoxamine with Dr. Carolyn Bramante, an Assistant Professor in the Division of Geriatrics, Palliative and Primary Care at the University of Minnesota Medical School.

Out of the 32 million patients with diabetes in the United States, 40 percent also have chronic kidney disease. But what’s even more alarming is that only 10 percent of these patients know they have chronic kidney disease. So what strategies can we use to address the unmet needs and barriers faced when managing patients with chronic kidney disease and type 2 diabetes? Joining Dr. Charles Turck to answer this and other key questions is Dr. Javier Morales, Associate Clinical Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell on Long Island.

Patients with diabetes-related chronic kidney disease (CKD) are at high risk for a number of adverse events over a relatively short period of time. So what do we have in terms of efficacious therapies that can help make a positive impact in that regard? Here to share what we need to know about non-steroidal mineralocorticoid receptor antagonists (MRAs) for the treatment of diabetes-related CKD is Dr. Mikhail Kosiborod, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute.

Approximately 34 million patients live with diabetes in the United States, and up to 40 percent of those patients also have chronic kidney disease (CKD). That’s why it’s so important to know how to identify and prevent CKD progression in patients with diabetes, and here to share key strategies is Dr. Gates Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.

In the ongoing battle against obesity, what does the SURMOUNT-1 study tell us about the role of tirzepatide? Dr. Ania Jastreboff, who is an Associate Professor of Medicine and the co-director of Weight Management and Obesity Prevention Program at Yale School of Medicine, chats with Dr. John Buse and this study’s findings.

The American Diabetes Association (ADA) published a new consensus report with the American College of Cardiology on heart failure in patients with diabetes. What does this report recommend—and how will these recommendations impact clinical practice? Dr. John Buse speaks with Dr. Rodica Pop-Busui from the University of Michigan about these updated heart failure recommendations.

The American Association of Clinical Endocrinology (AACE) released new recommendations for the diagnosis and management of NAFLD and NASH. To learn more about these updates, Dr. John Buse speaks with Dr. Kenneth Cusi, who is the Chief of the Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine at the University of Florida.

Pioglitazone was studied in the Insulin Resistance Intervention after Stroke trial, or IRIS for short. What do we need to know about it? Joining Dr. John Buse to share background and clinical data of the impacts observed is Dr. David Spence, a Professor Emeritus of Neurology and Clinical Pharmacology at Western University and the Director of the Stroke Prevention and Atherosclerosis Research Center in London, Ontario.

Intensive lifestyle interventions have shown to, if not prevent, significantly delay the onset of diabetes. But what do we need to know about these interventions? Joining Dr. John Buse to share clinical data and unravel the impacts of interventions in prediabetic patients is Dr. Samuel Dagogo-Jack from the University of Tennessee Health Sciences Center.

The obesity epidemic affects millions of patients around the world, but a new treatment option may be a game-changer for the treatment landscape. Lead author of the STEP 8 clinical trial, Dr. Domenica Rubino, joins Dr. John Buse to share the insights from this drug trial and how these key clinical findings may impact the obesity treatment landscape.